方盛制药：关于蛭龙通络片获得Ⅱ期临床试验总结报告的公告

Core Viewpoint - Fangsheng Pharmaceutical announced that its innovative traditional Chinese medicine, Zhilong Tongluo Tablets, has obtained the Phase II clinical research report as of September 22, 2025 [2] Company Summary - Fangsheng Pharmaceutical released an announcement regarding the progress of its research and development efforts [2] - The company is focusing on innovative traditional Chinese medicine, indicating a strategic direction towards enhancing its product pipeline [2] Industry Summary - The announcement reflects ongoing developments in the traditional Chinese medicine sector, particularly in the context of clinical research and innovation [2] - The successful completion of Phase II clinical trials is a significant milestone that may influence market perceptions and investment interest in the traditional Chinese medicine industry [2]